Our platform, DPX, has advanced a new class of immunotherapies that can be leveraged in multiple diseases and markets. In a proprietary process, we encapsulate active ingredients within our patented delivery technology.
At IMV, we believe we have found the key to bolster and direct the power of human immunity against diseases. Our bodies are hardwired with an elegant way to combat serious diseases and our novel platform makes use of it by delivering instructions to the immune system in a way that enables robust, targeted, and long-lasting response against specific targets.
Our proprietary technology is a unique “No-release” lipid-based delivery platform with no aqueous component in the final formulation. When administered, our formulation does not release components at the injection site, which allows it to continuously interact with and stimulate the immune system over an extended period of time. Thus, producing a more rapid, robust, and sustained immune response against specific disease targets.
We believe the method of delivering instructions to the human immune system is the differentiator that can create pivotal, sustained responses. Our DPX Platform has the potential to effectively deliver information that generates a target-specific immune response.
Our ability to activate the human immune system in a powerful and precise way is promising for not only cancer but infectious diseases, allergic responses and more. Presently, we are working with multiple partners to develop a clinical asset pipeline outside of oncology.